Clinical Trials: Gastrointestinal Cancer
Treatment Trials
Prostate
Therapeutic Area: Prostate
Principal Investigator: Dr. Susan Tannenbaum
Title: S9921: Adjuvant Androgen Deprivation Versus Mitoxantrone Plus Prednisone Plus Androgen Deprivation in Selected High Risk Prostate Cancer in Patients Following
Radical Prostatectomy
Description: The purpose of this study is to determine if patients with high risk localized prostate cancer that have had a prostatectomy will benefit from post-operative
treatment with one of the following combinations of drugs: bicalutamide (Casodex) + gosereline acetate (Zoladex) or mitoxantrone + prednisone given with Casodex + Zoladex.
Length/Duration: 24 months of treatment, 15 years of follow-up
Compensation: None
Location: Neag Comprehensive Cancer Center at the University of Connecticut Health Center
For more information, patient benefits, and to learn if you qualify:
please call 860-679-3066 or send an email to dnoel@uchc.edu
IRB #: 03-212
Sponsor: Eastern Oncology Cooperative Group (ECOG)
 Pancreas
Therapeutic Area: Prostate Cancer
Principal Investigator: Dr. Susan Tannenbaum
Title: S9346 Intermittent Androgen Deprivation in Patients with Stage D2 Prostate Cancer
Description: Patients with stage D2 prostate cancer are treated with 8 cycles of Casodex. If PSA levels stabilize, patients are placed on one of two treatment regimens.
Patients may be randomized to one of two treatment arms, either continuous treatment with Casodex for an additional 8 cycles, or an intermittent treatment with Casodex over the
same time period.
Length/Duration: Minimum of 8 months treatment, additional treatment depends on response
Compensation: None
Location: Neag Comprehensive Cancer Center at the University of Connecticut Health Center
For more information, patient benefits, and to learn if you qualify:
please call 860-679-3066 or send an email to dnoel@uchc.edu
IRB #: 96-212
Sponsor: Eastern Oncology Cooperative Group (ECOG) |
Research
done today will be the standard treatments of tomorrow.